Lilly demands doctors stop selling copycat weight-loss drugs
By Sriparna Roy and Christy Santhosh (Reuters) -Eli Lilly has sent cease-and-desist letters to U.S. healthcare providers in recent days to stop the promotion of the compounded versions of its drugs for weight loss and diabetes, as their supply increases, the company said on Wednesday. The letters were sent to telehealth companies, wellness centers and…